Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients

Diabetologia

Volumn 40, Issue 4, 1997, Pages 405-411

  Yokoyama, H ^a   Tomonaga, O ^a   Hirayama, M ^a   Ishii, A ^a   Takeda, M ^a   Babazono, T ^a   Ujihara, U ^a   Takahashi, C ^a   Omori, Y ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

angiotensin converting enzyme inhibitor; blood pressure; diabetic nephropathy; familial hypertension; proteinuria; smoking

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; SMOKING; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CEREBROVASCULAR DISORDERS; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY DISEASE; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NIFEDIPINE; PREDICTIVE VALUE OF TESTS; PROTEINURIA; RISK FACTORS; TIME FACTORS; TRIGLYCERIDES;

EID: 0030981911     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050694     Document Type: Article

References (36)

1. D'Amico G (1995) Renal replacement therapy throughout the world: the registries. Am J Kidney Dis 25: 113-118
2. Japanese Society for Dialysis Therapy (1996) An overview of regular dialysis treatment in Japan. J Jpn Soc Dial Ther 29: 1-22
3. Jacobson HR (1991) Chronic renal failure: pathophysiology. Lancet 338: 419-427
4. Parving HH, Smidt UM, Friiberg B, Bonnevie-Nielsen V, Andersen AR (1981) A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy. Diabetologia 20: 457-461
5. Viberti GC, Bilous RW, MacKintosh D, Keen H (1983) Monitoring glomerular function in diabetic nephropathy. Am J Med 74: 256-264
6. Parving HH, Andersen AR, Smidt UM, Svendsen PA (1983) Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet i: 1175-1178
7. Rossing P, Hommel E, Smidt UM, Parving HH (1993) Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 42: 715-719
8. Remuzzi G, Bertani T (1990) Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38: 384-394
9. Willams PS, Foss G, Bone JM (1988) Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. Q J Med 252: 343-354
10. Parving HH, Rossing P, Hommel E, Smidt UM (1995) Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience. Am J Kid Dis 26: 99-107
11. Mulec H, Johnsen SA, Wiklund O, Bjorck S (1993) Cholesterol, a risk factor in diabetic nephropathy? Am J Kidney Dis 22: 196-201
12. Krolewski AS, Warram JH, Christleib AR (1994) Hypercholesterolemia - a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int 45 [Suppl 45]: S125-S131
13. Nyberg G, Blohme G, Norden G (1987) Impact of metabolic control in progression of clinical diabetic nephropathy. Diabetologia 30: 82-86
14. Viberti GC, Bilous RW, MacKintosh D, Bending JJ, Keen H (1983) Long term correction of hyperglycaemia and progression of renal failure in insulin-dependent diabetes. BMJ 286: 598-601
15. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR (1991) Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 324: 78-84
16. Barzilay J, Warram JH, Bak M, Laffel LMB, Canessa M, Krowlewski AS (1992) Predisposition to hypertension: risk factor for nephropathy and hypertension in IDDM. Kidney Int 41: 723-730
17. Watanabe N, Kamei S, Ohkubo A, Tokuda K (1986) Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in Hitachi 726 automated analyzer. Clin Chem 32: 1551-1544
18. Parving HH, Rossing P (1994) The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. Curr Opin Nephrol Hypertens 3: 292-300
19. Gall MA, Nielsen FS, Smidt UM, Parving HH (1993) The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 36: 1071-1078
20. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF (1993) Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 118: 129-138
21. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462
22. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M (1992) Renal protective effect of enalapril in diabetic nephropathy. BMJ 304: 339-343
23. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Bolton WK (1994) Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int [Suppl] 45: S150-S155
24. Bakris GL, Barnhill BW, Sadler R (1992) Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 41: 912-919
25. Hemmelder MH, Zeeuw DD, Gansevoort RT, Jong PE (1996) Blood pressure reduction initiates the antiproteinuric effect of ACE inhibition. Kidney Int 49: 174-180
26. Yokoyama H, Deckert T (1996) Central role of TGF-β in the pathogenesis of diabetic nephropathy and macrovascular complications: a hypothesis. Diabet Med 13: 313-320
27. Zats R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner B (1986) Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930
28. Riser BL, Cortes P, Zhao X, Bernstein J, Dumler F, Narins RG (1992) Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest 90: 1932-1943
29. Fogo A, Ichikawa I (1989) Evidence for the central role of glomerular growth promoters in the development of sclerosis. Semin Nephrol 9: 329-342
30. Ichikawa I, Harris RC (1991) Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int 40: 583-596
31. Krolewski AS, Canessa M, Warram JH et al. (1988) Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med 318: 140-145
32. Stegmayr BG (1990) A study of patients with diabetes mellitus (type 1) and end-stage renal failure: tobacco usage may increase risk of nephropathy and death. J Intern Med 228: 121-124
33. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M (1994) Smoking is associated with progression of diabetic nephropathy. Diabetes Care 17: 126-131
34. Lowrie EG, Lew NL (1990) Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15: 458-482
35. Brazy PC, Stead WW, Fitzwilliam JF (1989) Progression of renal insufficiency: role of blood pressure. Kidney Int 35: 670-674
36. Praga M, Hernandez E, Montoyo C, Andres A, Ruilope LM, Rodicio JL (1992) Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 20: 240-248